Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?

Cancer Res (2008) 68 (1): 5–8.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Variations in the Anticancer Activity of Free and Bound Phenolics of Finger Millet (Eleusine coracana (L) Gaertn; Variety KMR-301) Seeds
  • Mahadevaswamy G. Kuruburu
  • Venugopal R. Bovilla
  • Rimshia Naaz
  • Zonunsiami Leihang
  • SubbaRao V. Madhunapantula
Phytomedicine Plus (2022) 2 (2): 100276.
Molecular Profile of Skin Cancer
  • Elena Porumb-Andrese
  • Mihaela Monica Scutariu
  • Ionut Luchian
  • Thomas Gabriel Schreiner
  • Ioana Mârţu
  • Vlad Porumb
  • Cosmin Gabriel Popa
  • Darius Sandu
  • Ramona Gabriela Ursu
Applied Sciences (2021) 11 (19): 9142.
New horizons in benzothiazole scaffold for cancer therapy: Advances in bioactivity, functionality, and chemistry
  • Prabodh Chander Sharma
  • Diksha Sharma
  • Archana Sharma
  • Kushal Kumar Bansal
  • Harish Rajak
  • Sunil Sharma
  • Vijay Kumar Thakur
Applied Materials Today (2020) 20: 100783.
Targeted drug delivery to melanoma
  • Qi Liu
  • Manisit Das
  • Yun Liu
  • Leaf Huang
Advanced Drug Delivery Reviews (2018) 127: 208.
Virtual screening of B-Raf kinase inhibitors: A combination of pharmacophore modelling, molecular docking, 3D-QSAR model and binding free energy calculation studies
  • Wen Zhang
  • Kai-Xiong Qiu
  • Fang Yu
  • Xiao-Guang Xie
  • Shu-Qun Zhang
  • Ya-Juan Chen
  • Hui-Ding Xie
Computational Biology and Chemistry (2017) 70: 186.
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
  • Raghavendra Gowda
  • Gregory Kardos
  • Arati Sharma
  • Sanjay Singh
  • Gavin P. Robertson
Molecular Cancer Therapeutics (2017) 16 (3): 440.
Targeting protein kinase-b3 (akt3) signaling in melanoma
  • SubbaRao V. Madhunapantula
  • Gavin P. Robertson
Expert Opinion on Therapeutic Targets (2017) 21 (3): 273.
A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors
  • Huiding Xie
  • Lijun Chen
  • Jianqiang Zhang
  • Xiaoguang Xie
  • Kaixiong Qiu
  • Jijun Fu
International Journal of Molecular Sciences (2015) 16 (12): 12307.
Targeting drivers of melanoma with synthetic small molecules and phytochemicals
  • Leah Ray Strickland
  • Harish Chandra Pal
  • Craig A. Elmets
  • Farrukh Afaq
Cancer Letters (2015) 359 (1): 20.
An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors
  • Huiding Xie
  • Yupeng Li
  • Fang Yu
  • Xiaoguang Xie
  • Kaixiong Qiu
  • Jijun Fu
International Journal of Molecular Sciences (2015) 16 (11): 27350.
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
  • Maria Romina Girotti
  • Grazia Saturno
  • Paul Lorigan
  • Richard Marais
Molecular Oncology (2014) 8 (6): 1140.
Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
  • Raghavendra Gowda
  • SubbaRao V. Madhunapantula
  • Arati Sharma
  • Omer F. Kuzu
  • Gavin P. Robertson
Molecular Cancer Therapeutics (2014) 13 (10): 2328.
Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
  • Raghavendra Gowda
  • SubbaRao V. Madhunapantula
  • Omer F. Kuzu
  • Arati Sharma
  • Gavin P. Robertson
Molecular Cancer Therapeutics (2014) 13 (7): 1679.
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
  • Edna F. Choo
  • Chee M. Ng
  • Leanne Berry
  • Marcia Belvin
  • Nicholas Lewin-Koh
  • Mark Merchant
  • Laurent Salphati
Cancer Chemotherapy and Pharmacology (2013) 71 (1): 133.
Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma
  • Arati Sharma
  • SubbaRao V. Madhunapantula
  • Raghavendra Gowda
  • Arthur Berg
  • Rogerio I. Neves
  • Gavin P. Robertson
The American Journal of Pathology (2013) 182 (4): 1151.
The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors
  • Jun Tang
  • Karen E. Lackey
  • Scott H. Dickerson
Bioorganic & Medicinal Chemistry Letters (2013) 23 (1): 66.
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
  • SubbaRao V. Madhunapantula
  • Arati Sharma
  • Raghavendra Gowda
  • Gavin P. Robertson
Pigment Cell & Melanoma Research (2013) 26 (6): 886.
Targeting sphingosine kinase-1 to inhibit melanoma
  • SubbaRao V. Madhunapantula
  • Jeremy Hengst
  • Raghavendra Gowda
  • Todd E. Fox
  • Jong K. Yun
  • Gavin P. Robertson
Pigment Cell & Melanoma Research (2012) 25 (2): 259.
Specifically targeting ERK1 or ERK2 kills Melanoma cells
  • Jianzhong Qin
  • Hong Xin
  • Brian J Nickoloff
Journal of Translational Medicine (2012) 10 (1)
Validation and application of a liquid chromatography–tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction
  • Bilin Chou
  • Ryan S. Adler
  • Min Meng
  • Shaundel Percey
  • Brian Dean
  • Cornelis E.C.A. Hop
  • Young G. Shin
Journal of Pharmaceutical and Biomedical Analysis (2012) 70: 354.
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
  • John M. Kirkwood
  • Lars Bastholt
  • Caroline Robert
  • Jeff Sosman
  • James Larkin
  • Peter Hersey
  • Mark Middleton
  • Mireille Cantarini
  • Victoria Zazulina
  • Karin Kemsley
  • Reinhard Dummer
Clinical Cancer Research (2012) 18 (2): 555.
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure
  • Stephanie Alexander
  • Peter Friedl
Trends in Molecular Medicine (2012) 18 (1): 13.
Melanoma Prevention Using Topical PBISe
  • Chin-Ying Chung
  • SubbaRao V. Madhunapantula
  • Dhimant Desai
  • Shantu Amin
  • Gavin P. Robertson
Cancer Prevention Research (2011) 4 (6): 935.
Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors
  • Ying Yang
  • Jin Qin
  • Huanxiang Liu
  • Xiaojun Yao
Journal of Chemical Information and Modeling (2011) 51 (3): 680.
Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling
  • Jian Chen
  • Qiong Shen
  • Mark Labow
  • L. Alex Gaither
Cancer Research (2011) 71 (12): 4280.
Therapeutic Implications of Targeting AKT Signaling in Melanoma
  • SubbaRao V. Madhunapantula
  • Gavin P. Robertson
Enzyme Research (2011) 2011: 1.
Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process
  • Edna F Choo
  • Bruno Alicke
  • Jason Boggs
  • Vikki Dinkel
  • Stephen Gould
  • Jonas Grina
  • Kristina West
  • Kapil Menghrajani
  • Yingqing Ran
  • Joachim Rudolph
  • Steve Wenglowsky
Xenobiotica (2011) 41 (12): 1076.
The Akt signaling pathway
  • SubbaRao V. Madhunapantula
  • Paul J. Mosca
  • Gavin P. Robertson
Cancer Biology & Therapy (2011) 12 (12): 1032.
Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells
  • Ana Burgeiro
  • Consuelo Gajate
  • EL Habib Dakir
  • Janny A. Villa-Pulgarín
  • Paulo J. Oliveira
  • Faustino Mollinedo
Anti-Cancer Drugs (2011) 22 (6): 507.
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
  • Gajanan S. Inamdar
  • SubbaRao V. Madhunapantula
  • Gavin P. Robertson
Biochemical Pharmacology (2010) 80 (5): 624.
Macrophage Inhibitory Cytokine-1 Regulates Melanoma Vascular Development
  • Sung Jin Huh
  • Chin-Ying Chung
  • Arati Sharma
  • Gavin P. Robertson
The American Journal of Pathology (2010) 176 (6): 2948.
MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo
  • Ying C. Henderson
  • Yunyun Chen
  • Mitchell J. Frederick
  • Stephen Y. Lai
  • Gary L. Clayman
Molecular Cancer Therapeutics (2010) 9 (7): 1968.
Viral Oncolysis That Targets Raf-1 Signaling Control of Nuclear Transport
  • Laura Riolobos
  • Noelia Valle
  • Eva Hernando
  • Beatriz Maroto
  • Michael Kann
  • José M. Almendral
Journal of Virology (2010) 84 (4): 2090.
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
  • Steven Whittaker
  • Ruth Kirk
  • Robert Hayward
  • Alfonso Zambon
  • Amaya Viros
  • Neus Cantarino
  • Annette Affolter
  • Arnaud Nourry
  • Dan Niculescu-Duvaz
  • Caroline Springer
  • Richard Marais
Science Translational Medicine (2010) 2 (35)
Targeted Molecular Therapy in Melanoma
  • Igor Puzanov
  • Keith T. Flaherty
Seminars in Cutaneous Medicine and Surgery (2010) 29 (3): 196.
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma
  • Cynthia Shepherd
  • Igor Puzanov
  • Jeffrey A. Sosman
Current Oncology Reports (2010) 12 (3): 146.
Characterization and performance of nucleic acid nanoparticles combined with protamine and gold
  • Robert K. DeLong
  • Uzma Akhtar
  • Michael Sallee
  • Brooke Parker
  • Stephanie Barber
  • Jie Zhang
  • Michael Craig
  • Richard Garrad
  • Anthony J. Hickey
  • Eric Engstrom
Biomaterials (2009) 30 (32): 6451.
Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates
  • Arati Sharma
  • Arun K. Sharma
  • SubbaRao V. Madhunapantula
  • Dhimant Desai
  • Sung Jin Huh
  • Paul Mosca
  • Shantu Amin
  • Gavin P. Robertson
Clinical Cancer Research (2009) 15 (5): 1674.
Pharmacodynamics of 2-{4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl}ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy
  • Harvey Wong
  • Marcia Belvin
  • Sylvia Herter
  • Klaus P. Hoeflich
  • Lesley J. Murray
  • Leo Wong
  • Edna F. Choo
Journal of Pharmacology and Experimental Therapeutics (2009) 329 (1): 360.
Biology of urothelial tumorigenesis: insights from genetically engineered mice
  • Xue-Ru Wu
Cancer and Metastasis Reviews (2009) 28 (3-4): 281.
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines
  • Narendra Wajapeyee
  • Varun Kapoor
  • Meera Mahalingam
  • Michael R. Green
Molecular Cancer Therapeutics (2009) 8 (11): 3009.
Phase 0 Clinical Trials: An Answer to Drug Development Stagnation?
  • Patricia M. LoRusso
Journal of Clinical Oncology (2009) 27 (16): 2586.
Identification of direct transcriptional targets ofV600EBRAF/MEK signalling in melanoma
  • Leisl M Packer
  • Philip East
  • Jorge S Reis-Filho
  • Richard Marais
Pigment Cell & Melanoma Research (2009) 22 (6): 785.
Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species
  • E. F. Choo
  • J. P. Driscoll
  • J. Feng
  • B. Liederer
  • E. Plise
  • N. Randolph
  • Y. Shin
  • S. Wong
  • Y. Ran
Xenobiotica (2009) 39 (9): 700.
Use of liposomes as drug delivery vehicles for treatment of melanoma
  • Melissa A. Tran
  • Rebecca J. Watts
  • Gavin P. Robertson
Pigment Cell & Melanoma Research (2009) 22 (4): 388.
Anticancer therapy: boosting the bang of Bim
  • Andrea Wahner Hendrickson
  • Xue Wei Meng
  • Scott H. Kaufmann
Journal of Clinical Investigation (2008) 118 (11): 3582.
RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells
  • Fengjuan Fan
  • Lin Feng
  • Jing He
  • Xiao Wang
  • Xiaomeng Jiang
  • Yixuan Zhang
  • Zhenzhen Wang
  • Yan Chen
Carcinogenesis (2008) 29 (6): 1157.
Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
  • Sven A. Lang
  • Philipp Schachtschneider
  • Christian Moser
  • Akira Mori
  • Christina Hackl
  • Andreas Gaumann
  • David Batt
  • Hans J. Schlitt
  • Edward K. Geissler
  • Oliver Stoeltzing
Molecular Cancer Therapeutics (2008) 7 (11): 3509.
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma
  • SubbaRao V. Madhunapantula
  • Dhimant Desai
  • Arati Sharma
  • Sung Jin Huh
  • Shantu Amin
  • Gavin P. Robertson
Molecular Cancer Therapeutics (2008) 7 (5): 1297.
Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas
  • Koichi Furukawa
  • Kazunori Hamamura
  • Hideyuki Nakashima
  • Keiko Furukawa
PROTEOMICS (2008) 8 (16): 3312.
  • Online ISSN 1538-7445
  • Print ISSN 0008-5472

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept